01Approach to the Critical Patient/attcp61

Immediate stabilization

›Airway and breathing priorities

›Respiratory failure from Q fever pneumonia

›SpO2 < 90% on room air

›PaO2 < 60 mmHg

›Rapidly escalating oxygen requirement

›If unable to maintain oxygenation, escalate to HFNC or NIV

›Intubation if refractory hypoxemia or fatigue

›ARDS pattern rare but reported with severe Q fever pneumonia

›Bilateral infiltrates with refractory hypoxemia

›Hemodynamic threats

›Myocarditis or pericarditis

›Chest pain with tachycardia out of proportion to fever

›Hemodynamic instability in approximately 1% of acute cases

›Sepsis physiology

›MAP < 65 mmHg

›Lactate >= 2 mmol/l

›If shock with suspected Q fever endocarditis, urgent cardiology consult

›Critical branching decisions

›Severe acute Q fever presentation

›Q fever pneumonia with respiratory distress

›Myocarditis or pericarditis suspected

›Meningoencephalitis with altered mental status

›Chronic Q fever emergency

›New or worsening heart failure in known valve disease

›Embolic event with culture-negative endocarditis picture

›Start empiric doxycycline 100 mg IV or PO when suspicion is high

›Do not delay for serologic confirmation

02History/hx65

Core presentation

›Classic febrile syndrome

›Fever onset

›Abrupt or gradual onset

›Fever often high, exceeding 40 degrees Celsius in 58% of pneumonia cases

›Headache character

›Severe, often retroorbital, may radiate to jaw

›Can mimic migraine or dental pain

›Myalgia and fatigue

›Prominent constitutional symptoms

›Chills and rigors common

›Incubation period 14 to 39 days, average approximately 20 days

›Respiratory symptoms

›Nonproductive cough in approximately 50% of pneumonia cases

›Upper respiratory symptoms less prominent than other CAP etiologies

›Dyspnea when pneumonia severe

›Pleuritic chest pain

›Pleural involvement in subset

›Pericarditis as alternative etiology

Exposure history

›Animal and occupational exposure

›Livestock contact

›Cattle, sheep, goats most common sources

›Birthing products, placental tissue, amniotic fluid highest risk

›Occupational risk

›Farmers, veterinarians, slaughterhouse workers

›Wool and hide handlers, laboratory workers

›Environmental exposure

03Physical Exam/exam51

Vital signs and general appearance

›Vital sign pattern

›Temperature

›High fever common, exceeding 40 degrees Celsius in majority

›Sustained fever rather than periodic

›Heart rate

›Tachycardia out of proportion to fever raises myocarditis concern

›Relative bradycardia can occur

›Blood pressure

›Hypotension if myocarditis or sepsis

›SBP < 90 mmHg triggers resuscitation

›General

›Ill-appearing and diaphoretic

›Toxic appearance less common in uncomplicated infection

Pulmonary exam

›Respiratory findings

›Lung auscultation

›Crackles or rales if pneumonia present

›Exam often benign relative to radiographic findings

›Work of breathing

›Accessory muscle use with severe pneumonia

›Inability to complete full sentences

Cardiac exam

›Cardiac findings

›Heart sounds and murmurs

›New murmur suggesting endocarditis

›Friction rub suggesting pericarditis

›S3 gallop suggesting heart failure

04Differential Diagnosis/ddx54

Life-threatening mimics

›Immediate threats to consider

›Culture-negative endocarditis

›Bartonella, Brucella, HACEK organisms

›ICD-10 I33.0

›Blood cultures negative in Q fever endocarditis

›Bacterial meningitis

›ICD-10 G00.9

›Severe headache and meningismus overlap

›Myocarditis from other causes

›ICD-10 I40.9

›Viral, autoimmune etiologies

›Sepsis from atypical pneumonia

›ICD-10 A41.9

›Hemodynamic instability

Zoonotic and atypical infections

›Overlapping zoonoses

›Brucellosis

›Similar animal exposure history

›Undulant fever and hepatitis

›ICD-10 A23.9

›Leptospirosis

›Animal exposure, fever, hepatitis, renal involvement

›ICD-10 A27.9

›Rocky Mountain spotted fever and rickettsial diseases

›Fever, headache, rash with tick exposure

›ICD-10 A77.0

›Tularemia

05Laboratory Tests/lt55

Serologic and microbiologic testing

›Serology gold standard

›Indirect immunofluorescence assay

›Most commonly used serologic method

›Paired acute and convalescent sera 3 to 6 weeks apart

›Fourfold rise in phase II IgG confirms acute Q fever

›Single phase II IgG >= 1:128 with compatible illness is probable acute infection

›Seroconversion occurs 7 to 15 days after symptom onset

›90% seroconvert by week 3

›Chronic Q fever serologic threshold

›Phase I IgG >= 1:1024 with identifiable nidus of infection

›Phase I IgG elevation distinguishes chronic from acute

›PCR testing

›Blood PCR for Coxiella burnetii DNA

›Sensitivity approximately 81%, specificity approximately 90% on serum

›Useful before seroconversion, first 2 weeks of illness

›Sensitivity lower in later disease stages

›Tissue or valve PCR

›Surgical specimens in endocarditis

›High yield when valvular disease present

Hematologic and inflammatory markers

›Complete blood count

›White blood cell count

›WBC typically normal; leukocytosis uncommon

›Relative lymphopenia in approximately 50% of cases

›Platelet count

›Thrombocytopenia possible in severe disease

›Inflammatory markers

06Diagnostic Tests/dt75

Scoring Systems

›Severity and risk stratification tools

›CURB-65 for pneumonia severity

›Confusion

›Urea > 7 mmol/l

›Respiratory rate >= 30 per minute

›Systolic BP < 90 mmHg or diastolic BP <= 60 mmHg

›Age >= 65 years

›Score 0 to 1 low risk outpatient candidate

›Score >= 3 high mortality risk and admission indicated

›Pneumonia Severity Index

›Broader comorbidity integration

›Useful when CURB-65 intermediate result

›Q fever specific risk assessment

›No validated Q fever specific scoring system

›Risk stratify by host factors for chronic disease

›Valvular disease and immunosuppression highest risk

›Modified Duke Criteria for endocarditis

›Major criterion: positive Q fever serology phase I IgG >= 1:800

›Used in conjunction with echocardiographic findings

MRI

›MRI cardiac indications

›Myocarditis evaluation

›Late gadolinium enhancement pattern for myocardial injury

›Pericardial enhancement in pericarditis

›ACC 2024 guidance supports CMR in suspected myocarditis

›MRI limitations in acute Q fever

›Availability and time constraints in acute setting

›Unstable patient is contraindication

›Non-compatible cardiac devices preclude use

›MRI for other complications

›Vascular infection

›Aortic aneurysm with periaortic inflammation

›Bone infection in osteomyelitis

›Brain MRI for neurologic complications

›Encephalitis signal changes

›Embolic stroke from endocarditis

CT

›CT chest findings in Q fever pneumonia

›Common patterns

›Segmental or lobar consolidation, often unilateral

›Single opacity most common pattern

›Upper lobe predilection in some series

›Patchy infiltrates in subset

›Ground glass opacification

›CT indication thresholds

›CXR equivocal with high clinical suspicion

›Failure to improve after 48 to 72 hours of treatment

›Complication assessment required

›Evidence basis

›CT chest demonstrates greater sensitivity than CXR for early infiltrates

›Voloudaki et al. 2000 characterizes CT findings in Q fever pneumonia

›CT angiography for vascular complications

›Aortic aneurysm and vascular graft infection

›Perianeurysmal fluid and fat stranding

›Wall thickening and enhancement

›Indication in chronic Q fever patients with vascular grafts

›Abdominal CT

›Hepatosplenomegaly assessment

›Granulomatous hepatitis pattern

›Fibrin ring granulomas characteristic but not pathognomonic

Ultrasound

›Echocardiography

›Transthoracic echocardiogram

›All patients with Q fever and risk factors for endocarditis

›Detection of vegetation, valve dysfunction, pericardial effusion

›Systematic TTE during acute Q fever recommended

›Melenotte et al. 2019 supports TTE during acute Q fever to detect subclinical endocarditis

›Transesophageal echocardiogram

›Superior sensitivity for vegetations on native and prosthetic valves

›Indicated when TTE non-diagnostic and suspicion high

›Required when prosthetic valve present

›Lung ultrasound

›Consolidation identification

›Tissue-like echotexture with air bronchograms

›Complementary to CXR

›Pleural effusion assessment

›Free fluid versus complex loculations

›Thoracentesis guidance

07Disposition/dispo43

Admission indications

›Inpatient admission required

›Pulmonary criteria

›Severe pneumonia with respiratory distress

›Hypoxemia SpO2 < 92% on room air

›CURB-65 score >= 3

›Cardiac criteria

›Suspected myocarditis, pericarditis, or endocarditis

›New murmur or embolic phenomena

›Hemodynamic instability

›Neurologic criteria

›Altered mental status or meningismus

›Suspected meningitis or encephalitis

›High-risk host factors

›Known valvular disease or prosthetic valve with acute Q fever

›Pregnancy with acute Q fever

›Severe immunosuppression

›Inability to tolerate oral medications

ICU indications

›Critical care triggers

›Respiratory failure

›Intubation requirement

›HFNC with rising oxygen requirement

›Hemodynamic instability

›Vasopressor requirement for MAP < 65 mmHg

›Cardiogenic shock from myocarditis or endocarditis

›Multiorgan dysfunction

›Rising lactate despite resuscitation

08Treatment/t60

Acute Q fever antibiotics

›First-line treatment

›Doxycycline oral

›100 mg PO twice daily

›Duration 14 days for uncomplicated acute Q fever

›Most effective when started within first 3 days of symptoms

›Treat empirically when suspicion high without waiting for serology

›Fever typically resolves within 72 hours of initiation

›IV formulation for severe illness

›Doxycycline 100 mg IV every 12 hours

›Transition to oral when clinically appropriate

›Alternative agents when doxycycline contraindicated

›Moxifloxacin

›400 mg PO or IV daily

›QTc monitoring required

›Clarithromycin

›500 mg PO twice daily

›Less evidence base than doxycycline

›Trimethoprim-sulfamethoxazole

›TMP 160 mg / SMX 800 mg PO twice daily

›Option in doxycycline contraindicated patients

›Contraindicated agents

›Beta-lactams and cephalosporins are ineffective against Coxiella burnetii

›Do not use penicillins, amoxicillin, or cephalosporins as primary treatment

Chronic Q fever treatment

›Standard chronic Q fever regimen

›Doxycycline plus hydroxychloroquine combination

›Doxycycline 100 mg PO twice daily

09Special Populations/sp51

Pregnancy

›Pregnancy-specific considerations

›Risk profile

›Miscarriage risk especially in first trimester

›Stillbirth and premature delivery risk

›Intrauterine growth restriction

›Recrudescence risk in subsequent pregnancies after prior Q fever

›Treatment in pregnancy

›Trimethoprim-sulfamethoxazole throughout pregnancy

›TMP 160 mg / SMX 800 mg PO twice daily for duration of pregnancy

›Doxycycline contraindicated in pregnancy due to teratogenicity

›Avoid conception for at least 1 month after acute Q fever treatment

›Postpartum management

›Transition to doxycycline plus hydroxychloroquine if chronic infection develops

›Long-term serologic follow-up postpartum mandatory

›Obstetric monitoring

›OB/GYN co-management required

›Fetal growth monitoring

›Avoid first trimester TMP-SMX if neural tube closure concern, discuss risks and benefits

Geriatric

›Older adult features

›Atypical presentation

›Afebrile infection more common

›Delirium or functional decline as presenting symptom

›Classic headache may be absent

›Higher chronic Q fever risk

›Valvular heart disease prevalence increases with age

›Endocarditis predominantly in men older than 40 years

10Background/b75

Epidemiology

›Incidence and distribution

›Global zoonosis

›Present worldwide except New Zealand and Antarctica

›Nationally notifiable disease in the United States

›CDC Category B bioterrorism agent

›Infection outcomes distribution

›Approximately 60% of infections are asymptomatic

›40% develop symptomatic acute illness

›Less than 5% progress to chronic persistent focalized infection

›Chronic Q fever mortality

›Up to 60% mortality if untreated chronic Q fever

›Reduced to less than 5% with appropriate treatment

›Endocarditis in chronic disease

›60 to 78% of chronic Q fever cases present as endocarditis

›Seasonal pattern

›Peak transmission February through May

›Coincides with lambing and calving season

›Demographic distribution

›Males greater than females for endocarditis manifestation

›Endocarditis predominantly in men older than 40 years

Pathophysiology

›Organism characteristics

›Coxiella burnetii biology

›Obligate intracellular gram-negative bacterium

›Unique biphasic antigen expression

›Phase I virulent form in natural host

›Phase II avirulent form in cell culture

›Environmental persistence

›Highly resistant to heat and desiccation

›Survives in environment for months to years

›Spore-like form enables long-range transmission

›Transmission pathways

›Primary route

›Inhalation of contaminated aerosols from infected livestock

›Birth products, placenta, amniotic fluid highest concentration

›Secondary routes

›Ingestion of unpasteurized milk rare but documented

›Tick transmission rare

›Person-to-person transmission extremely rare

›Disease mechanisms

›Acute infection

›C. burnetii infects monocytes and macrophages

›Inhibits phagolysosome acidification to survive intracellularly

›Cytokine dysregulation drives fever and systemic inflammation

›Chronic infection

›Persistent intracellular infection despite antibody response

›Sustained phase I IgG elevation reflects ongoing antigenic stimulation

›Granuloma formation in hepatitis pattern with fibrin ring granulomas

›Organ tropism

›Lungs, liver, and heart primary targets

›Bone and vascular endothelium in chronic disease

Therapeutic Considerations

›Antibiotic mechanism and rationale

›Doxycycline mechanism

›Inhibits bacterial protein synthesis

›Achieves high intracellular concentrations

›Efficacious against obligate intracellular pathogens

›Hydroxychloroquine rationale in chronic disease

›Alkalinizes phagolysosome, restoring doxycycline bactericidal activity

›Doxycycline is bacteriostatic alone but bactericidal when combined with hydroxychloroquine

›Combination essential for chronic Q fever treatment

›Beta-lactam inefficacy

›Coxiella burnetii intrinsically resistant to beta-lactams

›Cell wall structure differs from typical gram-negatives

›Beta-lactams and cephalosporins must not be used as primary therapy

›Treatment response markers

›Serologic response monitoring

›Phase I IgG titer decline over months confirms response

›Treatment continued until phase I IgG < 1:200

›Clinical response

›Fever resolution within 72 hours of doxycycline

›CRP normalization over weeks

›Evidence base

›CDC and Q Fever Working Group 2013 recommendations primary guidance document

›Anderson et al. MMWR 2013 foundational reference

›Kersh 2013 expert review on antimicrobial therapies

›Raoult, Marrie, Mege 2005 Lancet Infectious Diseases on natural history

11Patient Discharge Instructions/pdi38

copy discharge instructions

›Q Fever home care

›Take doxycycline exactly as prescribed for the full 14 days

›Take with food and a full glass of water to reduce stomach upset

›Avoid lying down for 30 minutes after taking the pill

›Avoid dairy products within 2 hours of taking doxycycline

›Do not stop the medication early even if you feel better

›Rest and hydration

›Rest at home for the first several days of illness

›Drink plenty of fluids to stay hydrated

›Fever is expected to improve within 3 days of starting antibiotics

›Infection control

›No person-to-person spread in routine circumstances

›Avoid contact with livestock, farm animals, and their birth products while ill

›Q fever is a reportable infection and public health has been notified

›Warning signs to return to the emergency department

›Breathing problems

›Shortness of breath at rest

›Rapid breathing or feeling unable to catch breath

›Cardiovascular warning signs

›Chest pain or pressure

›Palpitations or irregular heartbeat

›Swelling of the legs

›Neurologic warning signs

›New confusion or change in thinking

›Severe neck stiffness with headache

›Persistent or worsening fever after 3 to 4 days of antibiotics

›Inability to keep fluids or medications down

12References/r37

Guidelines and key sources

›Primary guidelines

›Anderson A et al., CDC and Q Fever Working Group, Diagnosis and Management of Q Fever, United States 2013, MMWR Recommendations and Reports 2013

›PMID 23535757

›Foundational guidance document for US clinical practice

›Kersh GJ, Antimicrobial Therapies for Q Fever, Expert Review of Anti-Infective Therapy 2013

›PMID 24073941

›Comprehensive antibiotic review

›Raoult D, Marrie T, Mege J, Natural History and Pathophysiology of Q Fever, Lancet Infectious Diseases 2005

›PMID 15792739

›Pathophysiology and epidemiology reference

Key clinical studies

›Diagnostic and imaging evidence

›Voloudaki AE et al., Q Fever Pneumonia CT Findings, Radiology 2000

›PMID 10831714

›CT characterization of Q fever pneumonia

›Gikas A et al., Q Fever Pneumonia Appearance on Chest Radiographs, Radiology 1999

›PMID 10207412

›Radiographic patterns reference

›Melenotte C et al., Acute Q Fever Endocarditis TTE Study, Clinical Infectious Diseases 2019

›PMID 30785186

›Supports systematic echocardiography in acute Q fever

›Treatment and outcomes evidence

›Carcopino X et al., Q Fever During Pregnancy, Annals of New York Academy of Sciences 2009

›PMID 19538266

›Pregnancy outcomes and treatment evidence

›Melenotte C et al., Clinical Features and Complications of Coxiella burnetii Infections, JAMA Network Open 2018

›French National Reference Center data

Evidence & Review

Evidence & Review